Clinical and Medical Oncology

Muhammad Imran Qadeer is from Sundas Foundation, Pakistan completed his work on Association Analysis of Kruppel like factor 1 (KLF1) And Secretion Associated Ras Related GTPase-1A (SAR1A) Genetic Polymorphisms with Hydroxyurea Response In β-Thalassemia Patients.

Tamar Safra is from Tel Aviv University, Tel Aviv, Israel completed his work on The effect of cannabis use on oncological outcomes in ovarian cancer patients treated with PARP inhibitors.

Dr Mari Aparici is a Clinical Professor at Stanford University. She is a Nuclear Molecular Physician with residencies in both Europe (Barcelona) and US (Stanford), and with Molecular imaging fellowships from Stanford University. She is a physician-scientist in the development of Molecular Imaging. She has more than 20 years of clinical and research experience in the field, more than 10 years of a leadership position as Chief Nuclear Medicine at the San Francisco VAMC as part of her prior appointment as a UCSF faculty member, and now as Head of the Theranostics and Nuclear Therapies program at Stanford University. She has published more than 100 papers in reputed journals, has been serving as an editorial board member of reputed journals, has been PI of NIH and non-NIH grants and serves as a member of several to committees at her University and several Societies. as her expertise in evaluation and passion in improving the health and wellbeing. Her open and contextual evaluation model based on responsive constructivists creates new pathways for improving healthcare. She has built this model after years of experience in research, evaluation, teaching and administration both in hospital and education institutions. The foundation is based on fourth generation evaluation (Guba& Lincoln, 1989) which is a methodology that utilizes the previous generations of evaluation: measurement, description and judgment. It allows for value-pluralism. This approach is responsive to all stakeholders and has a different way of focusing.

Olivier E Pardo has completed his Graduation from the Faculty of Pharmacy Paris-V, France where he was awarded a Doctorate in Industrial Pharmacy in 1997; PhD in Biochemistry and Molecular Biology at Imperial College-London in 2002 and Post-doctoral experience in the laboratory of Prof. Julian Downward at the CRUK-London Research Institute where he worked on the regulation of apoptotic cell death and cell migration. He created the Cellular Regulatory Networks lab at Imperial College, Department of Surgery and Cancer in 2006. His team focuses on understanding the molecular mechanisms underlying chemo-resistance and metastasis in lung and other cancers.

Abdalla Abotaleb is one of the most profound experts in healthcare policy and regulations in the Middle East. His expertise extends from HTA and reimbursement policies to regulatory and supply chain strategies in the public sector. He has been involved in the fields of health economics, outcomes research and reimbursement policy within the healthcare industry for 15 years, with experience across the pharmaceutical, biologicals, and vaccines. Currently, he is working for WHO as a Project Manager at Health Care Reforming area.